Marker Therapeutics
MRKR
Marker Therapeutics (MRKR) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.12
- EPS estimate
- −$0.36
- EPS surprise
- +66.67%
- Revenue surprise
- +70.53%
- Revenue
- $1.2M
- Revenue estimate
- $723,000.00
- Reported
- Nov 13, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 13, 2025 | −$0.36 | −$0.12 | +66.67% | $1.2M | SEC |
| Q2 2025 | Aug 14, 2025 | −$0.30 | −$0.25 | +17.74% | $880,600.00 | SEC |
| Q1 2025 | May 15, 2025 | −$0.53 | −$0.40 | +24.56% | $349,104.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.22 | −$0.41 | −86.36% | $2.3M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.39 | −$0.26 | +33.33% | $1.9M | SEC |
| Q2 2024 | Aug 14, 2024 | −$0.43 | −$0.25 | +41.98% | $1.2M | SEC |
| Q1 2024 | May 15, 2024 | −$0.25 | −$0.27 | −8.00% | $1.2M | SEC |
| Q4 2023 | Mar 26, 2024 | −$0.90 | $0.44 | +148.89% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$0.90 | −$0.34 | +62.22% | $257,606.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.80 | $0.29 | +136.25% | $762,658.00 | SEC |
| Q4 2022 | Mar 22, 2023 | −$1.00 | −$0.48 | +52.00% | $3.3M | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.30 | −$0.80 | +38.46% | $3.9M | — |
| Q2 2022 | Aug 11, 2022 | −$1.05 | −$1.10 | −4.76% | $790,508.00 | — |
| Q1 2022 | May 13, 2022 | −$1.20 | −$1.20 | +0.00% | $964,322.00 | — |
| Q4 2021 | Mar 17, 2022 | −$1.28 | −$1.10 | +13.73% | $1.2M | — |
| Q3 2021 | Nov 10, 2021 | −$1.28 | −$1.50 | −17.65% | $0.00 | — |
| Q2 2021 | Aug 10, 2021 | −$1.18 | −$1.30 | −10.64% | $0.00 | — |
| Q1 2021 | May 12, 2021 | −$1.45 | −$1.60 | −10.34% | $0.00 | SEC |
| Q4 2020 | Mar 9, 2021 | −$1.60 | −$1.70 | −6.25% | $0.00 | — |
| Q3 2020 | Nov 9, 2020 | −$1.45 | −$1.60 | −10.34% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Marker Therapeutics (MRKR) last report earnings?
Marker Therapeutics last reported on Nov 13, 2025, covering fiscal Q3 2025.
Did MRKR beat earnings estimates?
Yes. Marker Therapeutics reported EPS of −$0.12 for Q3 2025 against a −$0.36 estimate — a 66.67% beat.
How much revenue did MRKR report last quarter?
Marker Therapeutics reported $1.2M in revenue for Q3 2025, against a consensus estimate of $723,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.